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ABSTRACT
Objectives: To describe patterns of experimentation
with electronic cigarettes as a smoking cessation aid,
their self-reported impact on smoking cessation and to
identify factors associated with self-reported successful
quit attempts within the European Union (EU).
Design: A cross-sectional study.
Setting: 28 European Union member states.
Methods: We analysed data from wave 82.4 of the
Special Eurobarometer survey, collected in December
2014 from all 28 EU member states. The total
sample size was n=27 801 individuals aged
≥15 years; however, our analyses were conducted in
different subgroups with sample sizes ranging from
n=470 to n=9363. Data on e-cigarette
experimentation and its self-reported impact on
smoking cessation were collected. Logistic
regression models were used to assess factors
associated with experimentation of e-cigarettes as
cessation aids and with successful quitting. Logistic
regression was also used to assess changes in the
use of e-cigarettes as cessation aids between 2012
(using data from wave 77.1 of the Eurobarometer)
and 2014 in each member state.
Results: E-cigarettes were often experimented with
as a cessation aid, especially among younger
smokers (OR=5.29) and those who reported financial
difficulties (OR=1.33). In total, 10.6% of those who
had ever attempted to quit smoking and 27.4% of
those who did so using a cessation aid had
experimented with e-cigarettes as a cessation aid.
Among those who had used e-cigarettes as a
cessation aid, those with higher education were more
likely to have been successful in quitting (OR=2.23).
There was great variation in trends of use of
e-cigarette as a cessation aid between member
states.
Conclusions: Experimentation with e-cigarettes as a
potential cessation aid at a population level has
increased throughout the EU in recent years, and
certain population groups are more likely to
experiment with them as cessation aids. Research on
the potential population impact of these trends is
imperatively needed.
INTRODUCTION
Electronic cigarettes (e-cigarettes) have in-
creased in popularity among smokers,
ex-smokers and non-smokers in recent years.1–3
The e-cigarette industry often promotes them
as healthier alternatives which may help
smokers to quit or reduce smoking, as well as
to be used in places where regular smoking is
prohibited.4 The regulation of e-cigarettes has
varied among different countries. In the USA,
the regulatory authority of the Food and Drug
Administration was extended in 2016 to
include the manufacture, import, packaging,
labelling, advertising, promotion, sale and dis-
tribution of e-cigarettes.5 The European Union
(EU), on the other hand, regulates e-cigarettes
initially on their nicotine content, based on
which they come under the Consumers
Products Directive (for 0 mg/mL nicotine
concentrations), the Tobacco Products
Directive (TPD)(nicotine concentration >0
but<20 mg/mL) or as a pharmaceutical device
(if the product receives medical licensing). All
EU member states were required to comply
with the revised Tobacco Products Directive by
20 May 2016, but may have followed different
regulatory approaches in previous years.6
Central to the ongoing global debate on
the public health impact of e-cigarettes is
Strengths and limitations of this study
▪ The study has a large and representative sample
of respondents aged 15 years and older across
28 European Union (EU) member states; there-
fore, it provides reliable data for the entire EU.
▪ However, data were self-reported and could not
be verified with objective measurements.
▪ The study design was cross-sectional; therefore,
causal interpretations should be made with
caution.
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whether they are effective or not in aiding smoking ces-
sation or lead to a reduction or increase in use of
tobacco products. This is of critical importance as this
might determine whether e-cigarettes result in a net
harm or beneﬁt on population health.7 While some
studies suggest that e-cigarettes may be potentially effect-
ive in promoting smoking cessation and reducing cigar-
ette consumption,8 9 many others have failed to show
any beneﬁt, with a recent meta-analysis indicating that
overall e-cigarette use was associated with signiﬁcantly
lower odds of quitting smoking.10
The issue is further complicated by the lack of clarity
on the degree to which e-cigarettes are experimented
with as smoking cessation devices and how they may
impact tobacco use at a population level,11 which high-
lights the need for studies with large and representative
samples of populations. This is particularly important
considering the sharp increase in e-cigarette use in
Europe recently.3 Providing up-to-date estimates can be
particularly useful for policies and planning in tobacco
control. In addition to the issue of their effectiveness
overall, there are also questions around whether certain
groups may be more likely to be successful in quitting
with e-cigarettes. This would parallel ﬁndings that trad-
itional stop-smoking services are less likely to be effective
in certain groups.12
Hence, we conducted a secondary analysis of 2012
and 2014 Eurobarometer data in order to identify the
extent to which e-cigarettes may be experimented with
as a smoking cessation device, explore changes between
2012 and 2014 and identify sociodemographic factors
associated with experimentation of e-cigarettes as a ces-
sation aid and with self-reported successful quit attempts
following e-cigarette use.
METHODS
Data source
We conducted a secondary analysis of data from wave
82.4 of the Eurobarometer survey,13 collected in 28 EU
member states in November–December 2014. A multi-
stage sampling design was employed in order to collect
samples representative of the population aged ≥15 years,
both at an EU level and at the member state level.
Primary sampling units (PSU) were selected from each
region of each country, proportional to population size.
Subsequently, a sample of starting addresses was randomly
selected in each PSU and households were systematically
selected through a standard random route starting from
these addresses. Eurobarometer does not publish
response rates, but post-stratiﬁcation and population size
weighting were applied in each country/region, resulting
in nationally representative samples in terms of age,
gender and area of residence. Face-to-face interviews were
used to record self-reported data on tobacco use and
sociodemographic characteristics; all interviews were con-
ducted at participants’ homes and in the local language.
The total sample was n=27 801 individuals from all 28 EU
member states. Detailed data on the ﬁnal sample, the
sampling methodology and the questionnaire have been
made available in the ofﬁcial Eurobarometer report.14 We
also used data from wave 77.1 of Eurobarometer
(February–March 2012; n=26 751) to conduct compari-
sons with 2012. The data sets were publicly available and
all data were de-identiﬁed; thus, no ethical approval was
required.
Measures
E-cigarette use
Current and ever e-cigarette use was assessed with the
question “Regarding the use of electronic cigarettes or
any similar electronic devices (e-shisha, e-pipe), which
of the following statements applies to you?” and
responses included “You currently use electronic
cigarettes or similar electronic devices (eg, e-shisha,
e-pipe)”; “You used them in the past, but no longer use
them”; “You tried them in the past but no longer use
them”; “You have never used them”; and “Don’t know”.
The ﬁrst response was considered as an indication of
current use, while any of the ﬁrst three responses was
considered ‘ever use of e-cigarettes’.
Cigarette smoking
All participants were asked “Regarding smoking cigar-
ettes, cigars or a pipe, which of the following applies to
you?”. Responses included “You currently smoke”
(ie, current smokers); “You used to smoke but you have
stopped” (ie, ex-smokers); and “You have never smoked”
(ie, never smokers).
Use of cessation aids
Ex-smokers and current smokers who had ever tried to
quit (assessed using the question “Have you ever tried to
quit smoking?”) were asked “Which of the following did
you use in order to quit or to try to quit smoking?”.
Responses included “nicotine replacement medications
(like nicotine gum, patch or inhaler) or other medica-
tions”; “support from the doctor or other health profes-
sional or special stop-smoking services such as clinics or
specialists”; “telephone quit line services”; “internet quit
line services”; “alternative therapies such as acupuncture
or hypnosis”; “oral tobacco (snus) chewing or nasal
tobacco (snuff)”; “electronic cigarettes or any similar
device”; “smokeless cigarettes (other than electronic)”;
“you quit or you tried to quit without assistance”; and
‘other’. Each participant could report having used mul-
tiple cessation aids. Those who responded “don’t know”
were excluded from this analysis (n=291).
Effects of e-cigarette use on cigarette smoking
Respondents who responded that they had ever used e-
cigarettes and had ever smoked tobacco were asked
whether the use of electronic cigarettes or any similar
device had helped them to stop or reduce their tobacco
consumption. Response options included “Yes, you
stopped smoking tobacco completely”; “Yes, you stopped
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smoking tobacco for a while but started again”; “Yes, you
reduced your tobacco smoking but did not stop”; No,
you did not reduce your tobacco smoking at all”; “No
and actually you increased your tobacco smoking”.
Those who reported that they stopped smoking tobacco
for a while or permanently were considered successful
quitters following e-cigarette use. They are referred to
here as ‘self-reported successful quitters.’
Sociodemographic data
Data were collected on participants’ age (15–24; 25–39;
40–54; and ≥55 years), gender (male; female), age at
which they stopped full-time education: (≤15; 16–19 and
≥20 years old) and their difﬁculties in paying bills
during the past 12 months (almost never/never; and
from time to time/most of the time), which was used as
a proxy of ﬁnancial difﬁculties.
Statistical analysis
Descriptive results are presented as percentages with
95% CIs for categorical values and means with 95% CI
for continuous variables. Multilevel logistic regression
results are presented as adjusted ORs with 95% CI. For
our analyses, we used the following subsamples: former
smokers and current smokers who said that they had
ever tried to quit (n=9363); former smokers and current
smokers who had ever used a cessation aid (n=3407);
ever cigarette smokers who were also ever e-cigarette
users (n=2333); ever cigarette smokers who had also
experimented with e-cigarettes as a cessation aid
(n=681); and former smokers who had ever used e-
cigarettes (n=470) (see online supplementary table S1).
All regression analyses included sociodemographic
factors—gender; age; education; and difﬁculty in paying
bills—as independent variables. Adjusted multilevel
logistic regression analyses—with country being the
higher level variable—were performed for each of the
following outcomes:
1. Experimentation with e-cigarettes as a smoking cessa-
tion aid, separately among ex/current smokers who
had ever tried to quit and among the subset of them
who reported having used at least one cessation aid
in the past.
2. Having successfully quit smoking following the use of
e-cigarettes (self-reported), separately among those
who had ever used e-cigarettes and among those who
had experimented with e-cigarettes speciﬁcally as a
cessation aid.
Finally, an unadjusted logistic regression model was
ﬁtted for each country to assess the change in the odds
of having experimented with e-cigarette as a cessation
aid between 2012 and 2014. We used weights for each
survey year, but did not include sociodemographic vari-
ables in the model, due to the relatively small sample
sizes by country. Response options for e-cigarette and
smokeless cigarette were grouped together in the 2012;
thus, we included smokeless cigarettes in both waves for
consistency in the comparison, also considering that the
distinction between the two products may not be clear
among consumers.
All analyses were performed with Stata V.13.0; weights
provided in the ofﬁcial Eurobarometer data set were
used to account for the multistage sampling of the
survey, and observations with missing values were
excluded from the analysis.
RESULTS
Sociodemographic factors associated with
experimentation of e-cigarettes as a smoking cessation
aid
Among current and ex-smokers who had ever attempted
to quit smoking, 10.6% (95% CI 9.4% to 11.7%) had
tried to do so with e-cigarettes, while 61.4% (95% CI
59.8% to 63.1%) did not use any smoking cessation aid.
Within the subgroup of respondents who reported
the use of any cessation aid, the proportion who had
experimented with e-cigarettes to quit smoking was
27.4% (95% CI 24.7% to 30.1%). Furthermore, among
current smokers who reported using a smoking cessa-
tion aid in the past year, 43.6% (95% CI 37.5% to
50.0%) reported experimenting with e-cigarettes to try
to quit smoking.
As depicted in table 1, younger participants (15–
24-year-olds) were more likely than those aged 55+ to
have experimented with e-cigarettes as cessation aids
both among those who had tried to quit (OR=5.29; 95%
CI 3.89 to 7.19) and among those who had tried to quit
with the use of a cessation aid (OR=6.43; 95% CI 3.07 to
12.23). Among those who had tried to quit smoking in
the past, participants who reported facing ﬁnancial difﬁ-
culties were more likely to have experimented with e-
cigarettes as cessation aids (OR=1.33; 95% CI 1.11 to
1.59) in comparison to those who reported that they
were not facing ﬁnancial difﬁculties. This association,
however, was not statistically signiﬁcant either in the sub-
group of current smokers or in the subgroup of respon-
dents who had used a cessation aid to quit in the past
(table 1).
Changes in e-cigarette and smokeless cigarette use as
cessation aids between 2012 and 2014
Respondents who had attempted to quit smoking—suc-
cessfully or not—in the EU were more likely to report
that they have experimented with e-cigarettes (or/and
smokeless cigarettes) as cessation aids in 2014 compared
to 2012 (8.2% in 2014; 3.4% in 2012; OR=3.22; 95% CI
2.63 to 3.94). The increase was statistically signiﬁcant in
16 member states, but the magnitude of these changes
varied greatly between countries (ﬁgure 1). Results for
Croatia are not presented, as the country was not
included in the survey in 2012. Results for Portugal are
also not presented, because the number of respondents
who had used e-cigarettes (or/and smokeless cigarettes)
as cessation aids in the ﬁrst wave was <10 and hence the
95% CI was extremely wide.
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Self-reported impact of e-cigarette use on tobacco use
Among respondents who reported ever having used
both tobacco and e-cigarettes, 50.7% reported that e-
cigarettes did not help them reduce smoking or that
they actually smoked more after trying them, 21.8%
reported that they helped them reduce smoking con-
sumption, 14.4% reported that e-cigarettes helped them
to quit completely, while 13.1% reported that they quit
for a while but then relapsed. The proportion of self-
reported successful quitters among respondents who
explicitly reported having experimented with e-cigarettes
in order to quit was 23.5% (table 2).
Factors associated with successful quitting smoking
among e-cigarette users
Logistic regression analyses revealed that age, gender
and ﬁnancial difﬁculties were not associated with self-
reported successfully quitting smoking among any of the
two subgroups that were examined (table 3). Higher
education was positively associated with self-reporting a
successful quit attempt among those who experimented
with e-cigarettes as a cessation aid (OR=2.23; 95% CI
1.05 to 4.75); this association was less clear in the other
group.
DISCUSSION
Our analysis of representative data from 28 EU member
states has found that e-cigarettes were being experimen-
ted with by ∼1 in 10 smokers and one in four of those
who used a cessation aid to quit had experimented with
e-cigarettes, with higher percentages noted among
younger smokers. It is interesting to note that experi-
mentation with e-cigarettes as a cessation aid has more
than doubled throughout the EU in just 2 years,
although one in two among those who did so reported
that they did not help them reduce smoking or that they
actually smoked more after trying them.
More than 4 of 10 current smokers who made a quit
attempt during the year before the survey had experi-
mented with e-cigarettes as a way to stop smoking,
making it the most popular cessation aid within this
group. This ﬁnding highlights the increasing popularity
of e-cigarettes, despite the lack of scientiﬁc evidence or
recommendation, regarding their use as cessation aids.
It also serves as a reminder that advertising4 may over-
shadow scientiﬁc evidence,10 especially in novel pro-
ducts, such as e-cigarettes.
There was some indication that people of lower socio-
economic status were more likely to have experimented
with e-cigarettes as cessation aids. This may reﬂect
limited access to evidence-based smoking cessation pro-
ducts and methods among smokers with ﬁnancial difﬁ-
culties, who may turn to e-cigarettes which are
commercially available and do not require visits to
healthcare professionals, with the additional costs that
these may incur. Indeed, it has been previously shown
that smokers are more likely to use evidence-based cessa-
tion aids when costs are covered by the state15 and that
cost is an important barrier for the use of cessation aids,
especially in young smokers.16 Among those who experi-
mented with e-cigarettes in order to quit smoking,
respondents with a higher educational level were more
likely to report that they were successful in quitting. This
Table 1 Sociodemographic factors associated with the use of e-cigarettes as a smoking cessation aid in the EU
Among those who
have ever tried to
quit smoking
aOR (95% CI)
n=9363
Among current
smokers who have
ever tried to quit
smoking
aOR (95% CI)
n=3908
Among former
smokers
aOR (95% CI)
n=5455
Among those who
have ever used any
cessation aid to quit
smoking
aOR (95% CI)
n=3407
Age (years)
≥55 1.00 1.00 1.00 1.00
40–54 2.99 (2.40 to 3.74) 1.73 (1.33 to 2.25) 4.03 (2.57 to 6.32) 2.66 (2.09 to 3.38)
25–39 3.51 (2.78 to 4.43) 1.91 (1.45 to 2.51) 5.45 (3.43 to 8.66) 3.37 (2.61 to 4.36)
15–24 5.29 (3.89 to 7.19) 2.69 (1.89 to 3.82) 6.13 (3.07 to 12.23) 6.43 (4.48 to 9.23)
Gender
Female 1.00 1.00 1.00 1.00
Male 1.01 (0.86 to 1.19) 0.98 (0.81 to 1.18) 1.30 (0.93 to 1.81) 0.94 (0.78 to 1.12)
Difficulties paying bills
Never/almost never 1.00 1.00 1.00 1.00
From time to time/
most of the time
1.33 (1.11 to 1.59) 1.01 (0.82 to 1.24) 1.62 (1.13 to 2.33) 1.18 (0.97 to 1.44)
Age when stopped education (years)
Up to 15 1.00 1.00 1.00 1.00
16–19 1.32 (1.00 to 1.74) 1.26 (0.92 to 1.74) 1.75 (0.90 to 3.41) 1.20 (0.88 to 1.64)
≥20 1.01 (0.75 to 1.36) 1.07 (0.76 to 1.50) 1.55 (0.78 to 3.09) 0.92 (0.66 to 1.28)
EU, European Union.
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Figure 1 Change in use of
e-cigarettes as cessation aids
between 2012 and 2014 in the
EU (OR and 95% CI). *Data for
Croatia not shown, as it was not
included in the 2012 wave. Data
for Portugal not shown due to the
extremely wide CI. EU, European
Union.
Table 2 Self-reported impact of e-cigarette use on tobacco use in the EU
Among those who have
tried e-cigarettes
% (95% CI)
n=2333
Among those who have used
e-cigarettes as a cessation aid
% (95% CI)
n=681
Among ex-smokers who
have tried e-cigarettes
% (95% CI)
n=470
Stopped smoking tobacco
completely
14.4 (12.0 to 16.8) 23.5 (18.3 to 28.6) 57.1 (49.4 to 64.4)
Stopped smoking tobacco
for a while, but started
again
13.1 (10.7 to 15.5) 21.7 (16.6 to 26.8) 6.6 (3.9 to 11.1)
Reduced smoking but did
not stop
21.8 (19.0 to 24.6) 30.5 (24.8 to 36.2) 9.3 (5.9 to 14.2)
Did not reduce or
increased tobacco
smoking
50.7 (47.4 to 54.0) 24.3 (19.7 to 28.9) 27.0 (20.7 to 34.4)
EU, European Union.
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is consistent with ﬁndings from earlier studies, in which
more educated smokers were more likely to try to quit
and be successful in quitting,17 18 even though our study
did not have objective measures of quitting to validate
the respondents’ claims. In addition to that, the experi-
mentation of e-cigarette as a cessation aid could not be
linked to a particular quit attempt within the context of
the study.
The proportion of e-cigarette users who reported that
e-cigarette use helped them to quit smoking completely
was 14.4%, but reached 23.5% among those who expli-
citly mentioned that they experimented with them for
the purpose of quitting smoking. These numbers
suggest that a proportion of e-cigarette experimenters
may quit, but its relative effectiveness as a cessation aid
compared to well-established aids19 cannot be estimated
with this data set. Available evidence on the effectiveness
of interventions such as nicotine replacement therapy
(NRT) point to the additional beneﬁts of behavioural
support,20 and the interaction of e-cigarette use with this
remains to be seen. Self-reported outcomes of smoking
cessation can be ambiguous, especially when there is no
clearly deﬁned time frame of complete abstinence from
cigarette smoking. Moreover, there may be recall and
wish bias in reporting use of e-cigarette as a cessation
aid, which might inﬂate the proportion of successful
quitters among the group that explicitly reported using
them to stop smoking. In any case, the patterns of use
among e-cigarette users varied widely, as they were not
known to be following a protocol for smoking cessation;
as a result, the reported outcomes cannot be attributed
to a speciﬁc pattern of use, for example, daily or occa-
sional, dual or exclusive use. This may be an important
consideration, as it has previously been shown that fre-
quency of e-cigarette use and device type could
inﬂuence the outcome of a smoking cessation or reduc-
tion attempt.21–23
There was a signiﬁcant increase in the proportion of
people who experimented with e-cigarettes as a cessation
aid among those who had ever tried to quit within only
2 years. Considering that many of the respondents could
have quit smoking several years before the surveys, when
e-cigarettes did not exist, the recorded increase high-
lights the extent of the popularity of e-cigarettes in the
past few years. We found wide variation in the trends of
e-cigarette use as a cessation aid between EU member
states, with the majority of them showing a statistically
signiﬁcant increase. The differences between countries
may be attributed to different regulatory approaches
towards e-cigarettes, which lead to variation in the
overall use among the population,3 24 as well as to differ-
ent policies with regard to the cost of cessation aids and
whether this is partly or fully covered by the public
healthcare system in each country.15 Following the
implementation of the TPD across the EU, such differ-
ences in policies may be attenuated; therefore, it is
important to continue monitoring the trends in the use
of e-cigarettes in all member states and explore whether
this variation will continue to exist.
Strengths and limitations
This is the largest study to assess the reported experi-
mentation with e-cigarettes as smoking cessation devices
in a representative sample of respondents aged 15 years
and older across 28 EU member states. The large
sample size also allowed us to adjust for several con-
founding factors and minimise residual confounding.
We must state, however, that the detected associations
are useful for descriptive purposes and can generate
hypotheses, but no deﬁnitive conclusions can be drawn
Table 3 Factors associated with successful smoking cessation among e-cigarette in the EU
Among those who have tried
e-cigarettes
aOR (95% CI)
n=2261
Among those who have used
e-cigarettes as a cessation aid
aOR (95% CI)
n=665
Age (years)
≥55 1.00 1.00
40–54 0.73 (0.50 to 1.05) 0.59 (0.35 to 1.01)
25–39 0.94 (0.66 to 1.32) 0.86 (0.51 to 1.46)
15–24 0.87 (0.58 to 1.33) 0.54 (0.26 to 1.11)
Gender
Female 1.00 1.00
Male 1.22 (0.95 to 1.57) 1.30 (0.89 to 1.90)
Difficulties paying bills
Never/almost never 1.00 1.00
From time to time/most of the time 0.88 (0.68 to 1.14) 0.88 (0.59 to 1.29)
Age when stopped education (years)
Up to 15 1.00 1.00
16–19 1.21 (0.74 to 1.95) 1.45 (0.70 to 2.97)
≥20 1.60 (0.97 to 2.62) 2.23 (1.05 to 4.75)
EU, European Union.
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from such a survey, especially considering that data were
self-reported, without objective measurements that could
validate reports of quitting or of reduction in cigarette
smoking. We additionally do not have information on
how long self-reported quitters have reduced or abstained
from tobacco smoking. Moreover, we were not able to dir-
ectly compare e-cigarettes with other evidence-based ces-
sation methods (such as NRT in terms of outcomes),
which limits our ability to make conclusions regarding
the effectiveness of e-cigarettes in smoking cessation.
Finally, causal relationships cannot be evaluated due to
the cross-sectional design of the Eurobarometer survey.
CONCLUSIONS
The questions regarding the potential role of
e-cigarettes in smoking cessation, their efﬁcacy and
public health implications are pressing, as the popularity
of e-cigarettes is rapidly increasing. Our analyses of the
most recent Special Eurobarometer data revealed
increases in experimentation with e-cigarettes as a
smoking cessation device across the EU, but with
ambiguous results. Continued monitoring of the role of
e-cigarettes in Europe and beyond remains essential in
order to assess trends in their use and inform national
policies, especially as the regulatory landscape will be
inﬂuenced by the implementation of the TPD.
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